Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial
- Resource Type
- Article
- Source
- In
eClinicalMedicine July 2022 49 - Subject
- Language
- ISSN
- 2589-5370